Analysis of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Issue 30 (24th July 2020)

• Record Type: Journal Article
• Authors: Wu, Shihai; Quan, Rencui; Han, Ling; Zhang, Huaqing; Zhang, Baozhu; Xu, Gang; Li, Xianming
• Other Names: Ding. Jianxun section editor.
• Is Part Of: Medicine. Volume 99:Issue 30(2020)
• Publication Date: 2020-07-24
• Subjects: concurrent chemotherapy -- intensity-modulated radiotherapy -- nasopharyngeal carcinoma -- survival analysis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000021325
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: The present study aimed to retrospectively analyze the survival outcomes and prognostic factors for patients with nasopharyngeal carcinoma (NPC) receiving intensity-modulated radiotherapy (IMRT). Clinical data was collected from 691 patients with NPC receiving IMRT from January 2009 to August 2015. A survival analysis was performed and prognostic factors were analyzed using the Kaplan–Meier method, the Cox proportional hazards regression model, and the log-rank test. The median follow-up time was 62.8 months. Sixty-three patients experienced relapse, 44 cases (70%) of which occurred within 3 years. Six cases (9.5%) remained in remission for over 5 years. Seventy-two patients developed metastasis, 63 cases (87.5%) of which occurred within 3 years and only 1 case occurred after 5 years (1.3%). Five-year disease special survival (DSS), progression free survival, locoregional recurrence free survival, and distant metastasis free survival were 86.5%, 82.5%, 90.7%, and 89.4%, respectively in patients with NPC. Patients with stage III NPC with and without induction chemotherapy had 5-year DSS rates of 95.8% and 89.3%, respectively ( P = .00). Patients with stage IVa NPC with and without induction chemotherapy had 5-year DSS rates of 73.1% and 68.9%, respectively ( P = .04). The 5-year DSS rates of patients with stage III with or without concurrent chemotherapy were 92.8% and 85.5%, respectively ( P = .04). The 5-year DSS rates of patients with stage IV with or without concurrent chemotherapy were 72.7% and 53.0% ( P = .02). IMRT improves the survival rate of patients with NPC. Recurrence and metastasis mainly occur within 2 to 3 years after radiotherapy. Induction and concurrent chemotherapy improve the 5-year DSS of patients with locally advanced NPC.